Gerhard Symons

Gerhard Symons is a doctoral researcher at the Centre for Health Management, Imperial College Business School.

Gerhard Symons takes the Eurostar to Belgium to visit some of the leading biotechnology firms in the Bruges-Ghent-Leuven axis in the Flanders region, and unearths the origins of this fertile soil.

Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization.

Gerhard Symons realises that just one simple question can expose complex tensions between short-term profit motive, long-term market building and perception management of the industry.

This month, the Royal College of Physicians wil recommend a 'new covenant' between industry, clinicians and patients. The ABPI's Dr Richard Tiner, a working party member on the report, tells Gerhard Symons why transparency is key.

Industry is working more innovatively with academia on 'front-end' drug discovery. Gerhard Symons asks what this entails, and what are the challenges and rewards of this nascent paradigm?

The first wealth is health, wrote American thinker Ralph Waldo Emerson. Indeed, history has taught us (even before Emerson) that health and wealth are inextricably linked—the more money one has, the healthier one is likely to be.